Pharmabiz2 天
Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC
Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...
The American Journal of Managed Care3 天
Next-Gen Strategies for Resistance in EGFR-Mutated Lung Cancer
In the conclusion to our interview with Joshua K. Sabari, MD, which focused on the first-line approval of amivantamab (Ami; ...
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor ...
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
healthandpharma6 天
FDA Grants Breakthrough Status to Datopotamab Deruxtecan for Advanced EGFR-Mutated Lung Cancer
The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.
The Taipei Times6 天
4% of patients not covered for NHI EGFR-mutated lung cancer drugs: doctors
Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...
腾讯网6 天
【Cell子刊】战胜脑膜转移：中南大学张永昌团队揭示鞘内注射培美曲 ...
【导读】这项研究评估了鞘内培美曲塞（IP）对既往接受过治疗的表皮生长因子受体（EGFR）突变晚期非小细胞肺癌（NSCLC）患者脑膜转移瘤（LM）的治疗效果。2024年12月7日，中南大学湘雅医学院附属肿瘤医院张永昌教授团队在期刊《Heliyon》上发 ...